MONASH IVF GROUP LIMITED — Board/Management Information 2017

Jun 8, 2017

==> picture [596 x 94] intentionally omitted <==

ASX Announcement

Monash IVF Group Limited (ASX: MVF)

9 June 2017

Departure of Dr Lynn Burmeister

Monash IVF Group Limited (ASX:MVF, the "Company" or "Monash IVF") advises Dr Lynn Burmeister has tendered her notice to discontinue practicing at the Company.

Dr Burmeister's notice period expires on 11 September 2017 and the parties are currently discussing the terms of Dr Burmeister's cessation arrangements. The Company’s doctors are subject to lengthy non‐competes.

Monash IVF does not expect Dr Burmeister's cessation will have an impact on its financial results for the financial year ending 30 June 2017. Further, the impact of Dr Burmeister’s cessation should not be material in FY18. In FY19, there is potential for a percentage decline in Nett Profit After Tax (NPAT) of up to high single digits which may be offset by other market opportunities.

James Thiedeman, CEO and Managing Director said "While we wish Dr Burmeister the best for the future, we have over 100 doctors across Monash IVF’s clinics who are committed to providing world class IVF treatment and woman’s imaging services to our patients”.

…Ends…

Contact details

James Thiedeman Chief Executive Officer Monash IVF Group Limited Tel: +61 (0) 3 9420 8235

Michael Knaap Chief Financial Officer & Company Secretary Monash IVF Group Limited Tel: +61 (0) 3 9420 8235

About Monash IVF Group

Monash IVF Group is a leading provider of assisted reproductive services and specialist womens imaging and diagnostic services in Australia and Malaysia. The Group is a driving force in the development of assisted reproductive technologies and has many Australian and world firsts since the work of our pioneers who achieved the first IVF pregnancy in the world in 1973.